Lafayette, R. A. Et Al. 2023. eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefIgArd Phase 3 Trial. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN , vol.34, no.11S , 8.

Lafayette, R. A., Kristensen, J., Stone, A. M., Floege, J., Tesar, V., Trimarchi, H., ... Zhang, H.(2023). eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefIgArd Phase 3 Trial. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN , vol.34, no.11S, 8.

Lafayette, Richard Et Al. "eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefIgArd Phase 3 Trial," JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN , vol.34, no.11S, 8, 2023

Lafayette, Richard A. Et Al. "eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefIgArd Phase 3 Trial." JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN , vol.34, no.11S, pp.8, 2023

Lafayette, R. A. Et Al. (2023) . "eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefIgArd Phase 3 Trial." JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN , vol.34, no.11S, p.8.

@article{article, author={Richard A. Lafayette Et Al. }, title={eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefIgArd Phase 3 Trial}, journal={JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN}, year=2023, pages={8} }